Pfizer spinout SpringWorks will ship its first drug to the FDA before year’s end with PhIII win

SpringWorks Therapeutics thinks it has cemented the backbone for its first “pipeline-in-a-product” oncology treatment and will send it to the FDA before the clock strikes 2023 with a Phase III win on Tuesday.